In another study, CT-based radiomic analysis that quantified the temporal decrease in the tumor spatial heterogeneity and boundary infiltration were found to better predict the sensitivity EGFR-targeting therapy in metastatic CRC as compared to the standard endpoints, such as KRAS mutations and tumor shrinkage as per RECIST 1.1 (16)​. The gene discussed is KRAS; the disease is colorectal carcinoma.